Adult Stem Cells
Adult Stem Cells

Safety and Efficacy Study of the Patient's Own Cultured Fat-Derived Stem Cells for Fistulas due to Crohn's disease.

What? Phase II clinical trial evaluating safety and efficacy of the patient's own cultured fat-derived stem cells for the fistulas due to Crohn's disease.

Where? Participants receive care at the Asan Medical Center, Seoul, Republic of Korea.

Why? To evaluate the safety and effectiveness of the use of the patient's own cultured fat-derived stem cells to treat Crohn's disease.

How? Patients will experience a mini-liposuction of abdominal fat. Stem cells will be derived from that fat and administered to the patient.

When? This study is currently accepting patients. Results will be monitored during and/or at the end of a period of 8 weeks following the treatment. Several digital pictures will be taken over that period of time.

Who may participate? Patients must meet the following criteria:

  • Older than 18 years
  • Prior diagnosis of Crohn's disease
  • Patients who have Crohn's fistula
  • Negative for urine beta-HCG for woman of childbearing age
  • Agreement to participate, with signed informed consent

Who may not participate? Patients may not participate if they meet the following criteria:

  • Patients who have allergy to cow-derived materials, or an anesthetic
  • Patients with a diagnosis of auto immune disease other than Crohn's disease
  • Diagnosis of HBV, HCV, HIV and other infectious disease
  • Patients who have a symptom of septicemia
  • Patients with active Tuberculosis
  • Patient who are pregnant or breast-feeding
  • Patients who are unwilling to use an "effective" method of contraception during the study
  • Patients with a diagnosis of Inflammatory Bowel Disease other than Crohn's disease
  • Patients who are sensitive to Fibrin glue
  • Patients who have a clinically relevant history of abuse of alcohol or drugs, or habitual smoking
  • Insufficient adipose tissue for isolation of stem cells
  • Patients who are considered not suitable for the study by investigator
  • Patients with a diagnosis of active refractory Crohn's disease
  • Patients who have history of surgery for malignant cancer in the past 5 years
  • Patients who have external opening(s) greater than 2 cm diameter

For more information:

Contact: Chang-sik Yu, M.D
Asan Medical Center
Seoul, Republic of Korea, 138-736

All information is © 2012 by the Cell Therapy Foundation
Adult Stem Cells
Adult Stem Cells

* Designates sites with available clinical trials.

adult stem cells